These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28763435)

  • 1. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
    Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y
    Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
    Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
    Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination.
    Ren K; Wang X; Ma R; Chen H; Min T; Ma Y; Xie X; Wang W; Deng X; Zhou Z; Li K; Zhu K; Hao N; Dang C; Sun T; Zhang H
    Eur J Pharmacol; 2024 Nov; 983():177002. PubMed ID: 39293571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
    Chang YK; Choi H; Jeong JY; Na KR; Lee KW; Lim BJ; Choi DE
    PLoS One; 2016; 11(7):e0158810. PubMed ID: 27391020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dapagliflozin on colon cancer cell [Rapid Communication].
    Saito T; Okada S; Yamada E; Shimoda Y; Osaki A; Tagaya Y; Shibusawa R; Okada J; Yamada M
    Endocr J; 2015; 62(12):1133-7. PubMed ID: 26522271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
    Cassis P; Locatelli M; Cerullo D; Corna D; Buelli S; Zanchi C; Villa S; Morigi M; Remuzzi G; Benigni A; Zoja C
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
    Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
    Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate.
    Balzer MS; Rong S; Nordlohne J; Zemtsovski JD; Schmidt S; Stapel B; Bartosova M; von Vietinghoff S; Haller H; Schmitt CP; Shushakova N
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules.
    Kim JH; Ko HY; Wang HJ; Lee H; Yun M; Kang ES
    Diabetes Obes Metab; 2020 Mar; 22(3):373-382. PubMed ID: 31692240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
    Shaikh S; Rizvi SM; Shakil S; Riyaz S; Biswas D; Jahan R
    Biotechnol Appl Biochem; 2016; 63(1):145-50. PubMed ID: 25402624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
    Zhang Y; Thai K; Kepecs DM; Gilbert RE
    PLoS One; 2016; 11(1):e0144640. PubMed ID: 26741142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
    Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS
    Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.